Indifaxa

Rivaroxaban, the active ingredient in Indifaxa, is a Direct Factor Xa inhibitor presented as an oral tablet for oral use. It is used to reduce the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism. GNH USA supplies Indifaxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks across Europe, Asia and the Americas.

Rivaroxaban is a direct Factor Xa inhibitor used in several thromboembolic conditions.

- Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis and pulmonary embolism: provides treatment and secondary prevention. - Orthopedic surgery prophylaxis: prevents postoperative deep vein thrombosis.

Rivaroxaban may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bleeding gums: mild oral bleeding. - Nosebleeds: epistaxis. - Bruising: easy bruising of skin. - Gastrointestinal discomfort: nausea or dyspepsia. - Headache: mild to moderate. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Major hemorrhage: internal bleeding such as gastrointestinal or intracranial. - Hemorrhagic stroke: bleeding within the brain. - Spinal or epidural hematoma: bleeding in the spinal canal, especially after neuraxial procedures. - Liver injury: elevated transaminases or hepatitis. - Allergic reaction: severe rash, angioedema, or anaphylaxis. - Thrombocytopenia: low platelet count.

Before prescribing Indifaxa, clinicians should evaluate patient-specific risk factors. - Renal function: assess creatinine clearance prior to initiation. - Hepatic impairment: avoid in patients with severe liver disease. - Concomitant anticoagulants: avoid combining with other anticoagulants or antiplatelet agents unless clinically justified. - Surgery or invasive procedures: discontinue according to recommended interval before procedures. - Pregnancy and lactation: use only if potential benefit outweighs risk; limited data are available. - Store at below 25°C: keep in the original pack, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Combined use with other anticoagulants (e.g., warfarin, heparin): heightened bleeding risk. - Antiplatelet agents at high doses (e.g., clopidogrel, aspirin): increased bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise levels. - NSAIDs (e.g., ibuprofen, naproxen): additive gastrointestinal bleeding risk. - SSRIs or SNRIs (e.g., sertraline, duloxetine): may increase bleeding tendency.